Faculty Opinions recommendation of Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.

Open Label ◽

Genotype 4 ◽

Treatment Naïve ◽

Open Label Trial

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

The Lancet ◽

10.1016/s0140-6736(15)60159-3 ◽

2015 ◽

Vol 385 (9986) ◽

pp. 2502-2509 ◽

Cited By ~ 187

Author(s):

Christophe Hézode ◽

Tarik Asselah ◽

K Rajender Reddy ◽

Tarek Hassanein ◽

Marina Berenguer ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Open Label ◽

Genotype 4 ◽

Treatment Naïve ◽

Open Label Trial

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

Gastroenterology ◽

10.1053/j.gastro.2015.07.001 ◽

2015 ◽

Vol 149 (4) ◽

pp. 971-980.e1 ◽

Cited By ~ 59

Author(s):

Eric Lawitz ◽

Mihály Makara ◽

Ulus Salih Akarca ◽

Paul J. Thuluvath ◽

Liliana Lucia Preotescu ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Chronic Hepatitis C Virus

Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis

Journal of Hepatology ◽

10.1016/s0168-8278(17)31945-1 ◽

2017 ◽

Vol 66 (1) ◽

pp. S728-S729 ◽

Cited By ~ 1

Author(s):

P. Mantry ◽

R. Reddy ◽

E. Cohen ◽

G. Everson ◽

A. Ramji ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Decompensated Cirrhosis ◽

Efficacy And Safety ◽

Genotype 1 ◽

Genotype 4 ◽

Chronic Hepatitis C Virus

951 – Efficacy and Safety of Glecaprevir/Pibrentasvir Treatment for 8 Weeks in Treatment-Naïve Patients with Chronic Hepatitis C Virus Infection Without Cirrhosis Or with Compensated Cirrhosis: Analysis of Data Pooled from Phase 2 and 3 Studies

Gastroenterology ◽

10.1016/s0016-5085(19)40030-9 ◽

2019 ◽

Vol 156 (6) ◽

pp. S-1218

Author(s):

Julio Gutierrez ◽

Eli Zuckerman ◽

Andrew Ustianowski ◽

Susanna Naggie ◽

Florin Caruntu ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Efficacy And Safety ◽

Compensated Cirrhosis ◽

Treatment Naïve

Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single‐arm, open‐label, phase 3 trial

Journal of Gastroenterology and Hepatology ◽

10.1111/jgh.15412 ◽

2021 ◽

Author(s):

Fei Kong ◽

Xiaoyu Wen ◽

Xiaofeng Wen ◽

Xiaozhong Wang ◽

Guicheng Wu ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Faculty Opinions recommendation of Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725275636.793502522 ◽

2014 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Liver Fibrosis ◽

Virus Infection ◽

Efficacy And Safety ◽

Advanced Liver Fibrosis ◽

Treatment Naïve

Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(18)30343-1 ◽

2019 ◽

Vol 4 (2) ◽

pp. 127-134 ◽

Cited By ~ 32

Author(s):

Lai Wei ◽

Seng Gee Lim ◽

Qing Xie ◽

Kính Nguyen Văn ◽

Teerha Piratvisuth ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

THU-198-Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies

Journal of Hepatology ◽

10.1016/s0618-8278(19)30473-6 ◽

2019 ◽

Vol 70 (1) ◽

pp. e251 ◽

Cited By ~ 1

Author(s):

Eli Zuckerman ◽

Julio Gutierrez ◽

Andrew Ustianowski ◽

Susanna Naggie ◽

Florin Alexandru Caruntu ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Efficacy And Safety ◽

Compensated Cirrhosis ◽

Treatment Naïve

Efficacy and safety of a herbal mixture (Viron® tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study

Drug Design Development and Therapy ◽

10.2147/dddt.s77168 ◽

2015 ◽

pp. 799

Author(s):

Mostafa Yakoot ◽

Hisham Shawkat ◽

Tarek Shawkat ◽

Sherine Helmy

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Proof Of Concept ◽

Efficacy And Safety ◽

Open Label ◽

Chronic Hepatitis C Virus

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trial

Liver International ◽

10.1111/liv.14633 ◽

2020 ◽

Vol 40 (11) ◽

pp. 2685-2693

Author(s):

Yanhang Gao ◽

Fei Kong ◽

Guangming Li ◽

Cheng Li ◽

Sujun Zheng ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Open Label ◽

Phase 3 ◽

Open Label Phase